-40%

est. 2Y upside i

Series D+

Legacy helps you test, improve, and freeze your sperm

Rank

#3922

Sector

Fertility Tech

Est. Liquidity

~3Y

Data Quality

Data: High

Legacy operates in a growing male fertility market with established partnerships and recent product innovations.

Last updated: March 10, 2026

Bull (25%)+100%

Legacy leverages its new comprehensive motility testing and vasectomy clinic solutions to significantly accelerate market penetration and expand its provider network. Revenue grows aggressively to $40M in two years, and its strong competitive position and profitability justify a premium 10x revenue multiple, leading to a $400M valuation.

Base (30%)+7%

Legacy continues to grow its revenue through existing channels and moderate adoption of new offerings. Revenue reaches $20M in two years. However, market multiples for HealthTech normalize, and despite profitability, Legacy's valuation multiple compresses to 8x revenue, resulting in a $160M valuation.

Bear (45%)-60%

Intense competition from incumbents like Ro, coupled with a high initial valuation, leads to slower-than-expected growth and significant multiple compression. Revenue grows to $12M in two years, but the valuation multiple drops to 5x revenue, leading to a $60M valuation, wiping out most common-stock value given liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

33%

Investors hold $50M in liquidation preferences ahead of common stock, meaning common shareholders would only see returns if the exit valuation exceeds $50M.

Dilution Risk

moderate

As a Series B company, further funding rounds are likely before an exit, which will lead to additional dilution for common shareholders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Legacy's equity.

Questions to Ask at the Interview

Strategic questions based on Legacy's data — designed to show you've done your homework.

  • 1

    “With major players like Ro acquiring competitors in the at-home fertility space, how does Legacy plan to maintain its competitive moat and differentiate its offerings beyond clinical standards?”

  • 2

    “Given the current $9M revenue and $150M valuation, what specific growth strategies and revenue targets are in place to justify and grow beyond the current valuation multiple over the next two to three years?”

  • 3

    “Considering the Series B funding and the $50M in total capital raised, what is the company's anticipated timeline and strategy for a liquidity event, and how is employee equity structured to ensure meaningful returns for common shareholders?”

Community

Valuation Sentiment

Our model estimates -40% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.